Document Detail

Easing the economic burden of acute coronary syndromes: cost-effectiveness of emerging therapies.
MedLine Citation:
PMID:  17203989     Owner:  NLM     Status:  MEDLINE    
Although only part of the entire treatment regimen, antithrombotic therapy represents a large portion of the total costs associated with acute coronary syndromes (ACS) treatment. Unfractionated heparin (UFH), the mainstay of antithrombotic therapy, carries the risk of bleeding and associated interventions, and must be closely monitored. UFH therapy also has an increased risk of heparin-induced thrombocytopenia (HIT) and osteoporosis. These drawbacks prompted the development of newer antithrombotic agents, particularly low molecular weight heparins (LMWH) and factor Xa inhibitors. LMWH have several clinical advantages over UFH and has been demonstrated to be more effective than UFH in ACS. Because UFH is inexpensive, newer therapies need to demonstrate economic attractiveness over UFH. In addition to acquisition costs, it is important to consider the cost of all key components throughout the continuum of care. Health economic analyses show that the clinical advantages of the LMWH enoxaparin are also likely to result in net cost-saving benefits, due to reductions in diagnostic catheterization, percutaneous transluminal coronary angioplasty, and intensive care unit length of stay. Fondaparinux, an indirect inhibitor of factor Xa, does not require routine monitoring or multiple daily dosing, and is unlikely to interact with HIT antibodies. Large randomized clinical trials have shown that fondaparinux is at least as safe and efficacious as enoxaparin or UFH in the prevention of venous thromboembolism (VTE) and treatment of deep vein thrombosis or pulmonary embolism. Data from 2 recently published trials are similarly indicating noninferiority of fondaparinux in ACS patients. Health economic analysis of fondaparinux treatment is currently limited to VTE scenarios but point to a cost benefit associated with fondaparinux compared with enoxaparin.
Edith A Nutescu
Related Documents :
18937859 - Duplex scan in patients with clinical suspicion of deep venous thrombosis.
16475039 - Advances in the diagnosis of venous thromboembolism.
19008109 - Thromboembolic disease after total knee replacement: experience of 5100 cases.
24896329 - Hyperhomocysteinemia promotes vascular remodeling in vein graph in mice.
17060659 - Diagnosis and treatment of deep-vein thrombosis.
15741959 - Diagnosis and management of iliac vein compression syndrome.
8076959 - Dual exposure and repair technique for ruptured aneurysms of aortic sinus of valsalva.
16112729 - Umbilical arterial thrombosis with vascular wall necrosis: clinicopathologic findings o...
21046509 - Stent graft implantation combined with coil embolization and external-internal iliac ar...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of managed care     Volume:  12     ISSN:  1088-0224     ISO Abbreviation:  Am J Manag Care     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2007-01-05     Completed Date:  2007-04-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9613960     Medline TA:  Am J Manag Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S444-50     Citation Subset:  H    
Department of Pharmacy Practice, University of Illinois at Chicago, 833 S Wood St, Rm 164, MC886, Chicago, IL 60612, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Cardiovascular Diseases / drug therapy*
Cost of Illness*
Cost-Benefit Analysis
Fibrinolytic Agents / economics*,  therapeutic use
Thrombosis / drug therapy,  prevention & control
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New treatment options for acute coronary syndromes.
Next Document:  Human papillomavirus and cervical cancer: burden of illness and basis for prevention.